CoChat

Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud

Open access
Hill, Andrew, Mirchandani, Manya, Pilkington, Victoria · 2022 · Open Forum Infectious Diseases

Published version of a preprint

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index; 6 of the 20 sources its claims cite were checked for support.

Abstract

Ivermectin has become a controversial potential medicine for coronavirus disease 2019. Some early studies suggested clinical benefits in treatment of infection. However, the body of evidence includes studies of varying quality. Furthermore, some trials have now been identified as potentially fraudulent. We present a subgroup meta-analysis to assess the effects of stratifying by trial quality on the overall results. The stratification is based on the Cochrane Risk of Bias measures and raw data analysis where possible. The results suggest that the significant effect of ivermectin on survival was dependent on largely poor-quality studies. According to the potentially fraudulent study (risk ratio [RR], 0.08; 95% CI, 0.02-0.35), ivermectin improved survival ~12 times more in comparison with low-risk studies (RR, 0.96; 95% CI, 0.56-1.66). This highlights the need for rigorous quality assessments, for authors to share patient-level data, and for efforts to avoid publication bias for registered studies. These steps are vital to facilitate accurate conclusions on clinical treatments.

Overview

CoChat Summary

TL;DR

This subgroup meta-analysis found that ivermectin’s apparent survival benefit in COVID-19 depended on including poor-quality or potentially fraudulent trials. After excluding high-risk and fraudulent studies, the survival effect became nonsignificant.

Key findings

  • Across all 12 survival studies (2628 participants), ivermectin was associated with a significant 51% increase in survival (95% CI, 0.28–0.86; P = .01).
  • Excluding the potentially fraudulent Elgazzar study reduced the effect to a borderline significant 38% increase in survival (95% CI, 0.39–0.99; P = .05).
  • Excluding high-risk-of-bias studies yielded a nonsignificant 10% increase in survival (95% CI, 0.57–1.42; P = .66), and excluding studies with some concerns yielded a nonsignificant 4% increase (95% CI, 0.56–1.66; P = .90).
  • The potentially fraudulent study reported an RR of 0.08 (95% CI, 0.02–0.35), suggesting ivermectin improved survival about 12 times more than in low-risk studies (RR, 0.96; 95% CI, 0.56–1.66).

Methods

  • The authors conducted a subgroup meta-analysis of clinical trials evaluating ivermectin for treatment of COVID-19, stratifying by trial quality and risk of bias.
  • Trials were identified by systematic searching of 8 databases; quality was assessed with Cochrane RoB 2 and CONSORT, plus additional checks of baseline characteristics via chi-square tests, randomization dates, recruitment balance across centers, and patient-level databases where available for duplicate participants or unexpected homogeneity/heterogeneity.
  • The survival analysis included 12 studies with 2628 participants: 4 low risk, 4 some concerns, 3 high risk, and 1 potentially fraudulent study.

Limitations

  • The paper states that a key limitation of meta-analyses is the quality and completeness of available evidence, and that existing risk-of-bias tools are insufficient because they assume studies report accurate and complete findings.
  • The paper states that publication bias affects meta-analyses, with positive and significant results more likely to be reported, and notes that not all registered trials have reported findings.
  • The text makes evident that the analysis depends on published data and patient-level databases only “where available,” and that some included studies had unclear randomization, allocation concealment, blinding, or analyzed-participant details.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/ofid/ofab645

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Survival effects of ivermectin.
Figure 1. Survival effects of ivermectin.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

6 Valid · 1 Not valid · 12 Not checked · 17 Own results and interpretations

12 more claims

Create a free account to see all 36 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 11
  • It may state two separate claims as one. 10

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

3 of 3

Citations

Cites

3 retracted

Show all 15 references

Cited by

See all 57

Metadata

Authors
Hill, A., Mirchandani, M., & Pilkington, V.
Affiliations
  • University of Liverpool (GB)
  • Imperial College London (GB)
  • University of Oxford (GB)
Corresponding author
Mirchandani, Manya
Venue
Open Forum Infectious Diseases
Published
2022-01-17
Volume
9
Issue
2
Pages
ofab645-ofab645
ISSN
2328-8957 (ISSN-L)
OpenAlex
W4206432189
Cited by
57
References
15
Citations by year
2026: 2 · 2025: 4 · 2024: 15 · 2023: 10 · 2022: 26
FWCI
6.72
Type
journal article
Language
en
Open access
Locations
  • Open Forum Infectious Diseases (publishedVersion, cc-by-nc-nd)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Rainwater Charitable Foundation
Topics
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Keywords
ivermectin, COVID-19 pandemic, SARS-CoV-2, trial quality, risk of bias, publication bias, health care fraud, survival, antiviral therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud. https://app.cochat.ai/papers/10.1093/ofid/ofab645
The paper
Hill, A., Mirchandani, M., & Pilkington, V. (2022). Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud. Open Forum Infectious Diseases. https://doi.org/10.1093/ofid/ofab645

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.